Numinus Wellness Inc (FRA:LR23)

€ 0.0406 -0.0094 (-18.8%) Market Cap: 15.10 Mil Enterprise Value: 14.94 Mil PE Ratio: 0 PB Ratio: 2.10 GF Score: 0/100

Q2 2024 Numinus Wellness Inc Earnings Call Transcript
Apr 15, 2024

€0.0456 (-34.86%)

Earnings
Q1 2024 Numinus Wellness Inc Earnings Call Transcript
Jan 15, 2024

Earnings
Q3 2023 Numinus Wellness Inc Earnings Call Transcript
Jul 17, 2023

€0.1576 (-8.80%)

Earnings
Numinus Wellness Inc at OTC Markets Small Cap Growth Investor Conference (Virtual) Transcript
Jul 13, 2023
Q2 2023 Numinus Wellness Inc Earnings Call Transcript
Apr 13, 2023

€0.1368 (-4.87%)

Earnings
Numinus Wellness Inc Annual Shareholders Meeting Transcript
Feb 15, 2023
Q1 2023 Numinus Wellness Inc Earnings Call Transcript
Jan 16, 2023

€0.1605 (+7.00%)

Earnings
Numinus Wellness Inc at OTC Markets KCSA Mental Health Investor Conference Transcript
Dec 15, 2022
Q4 2022 Numinus Wellness Inc Earnings Call Transcript
Nov 29, 2022

€0.175

Earnings
Q3 2022 Numinus Wellness Inc Earnings Call Transcript
Jul 14, 2022

€0.178 (-2.20%)

Earnings
Q2 2022 Numinus Wellness Inc Earnings Call Transcript
Apr 14, 2022

€0.37 (+2.78%)

Earnings
Q1 2022 Numinus Wellness Inc Earnings Call Transcript
Jan 20, 2022

€0.482 (-3.98%)

Earnings
Q4 2021 Numinus Wellness Inc Earnings Call Transcript
Dec 09, 2021

€0.3508 (-4.26%)

Earnings

Q1 2024 Numinus Wellness Inc Earnings Call Transcript

Jan 15, 2024 / 10:30PM GMT

Transcript

Operator

Good afternoon and welcome to the Numinus Wellness, Inc. first-quarter of fiscal 2024 results conference call. A question-and-answer session for analysts and institutional investors will follow the formal remarks. As a reminder, this call is being recorded. I would now like to turn the conference call over to your host, Craig McPhail. Please proceed.

Craig McPhail Numinus Wellness

Inc. - IR

Thank you, operator. Good afternoon, everyone, and thank you for joining us for our fiscal first quarter 2024 results conference call. Discussing Numinus' performance today, Payton Nyquvest, Founder and CEO; and Nikhil Handa, Chief Financial Officer. Joining them for analyst questions at the end of our formal remarks are Reid Robison, Chief Clinical Officer; and Paul Thielking, Chief Science Officer.

The following discussion may include forward-looking statements that are based on current expectations and are subject to a number of risks and uncertainties. The risks and uncertainties that could cause our actual financial and operating results to differ

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.